Page last updated: 2024-09-23

histamine phosphate

Description

histamine phosphate : A phosphate salt that is the diphosphate salt of histamine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID65513
CHEMBL ID3989520
CHEBI ID51193
SCHEMBL ID123245
MeSH IDM0089478

Synonyms (56)

Synonym
einecs 200-118-4
4-(2-aminoethyl)imidazole di-acid phosphate
histamine phosphate
4-(2-aminoethyl)imidazole bis(dihydrogen phosphate)
histamine biphosphate
histamine phosphate [usp]
histamine phosphate (1:2)
2-imidazol-4-ylethylamine orthophosphoric acid (1:2)
histamine diphosphate
histamine dihydrogen phosphate
histamine acid phosphate
1h-imidazole-4-ethanamine, phosphate (1:2)
histamine phosphate (tn)
D04445
51-74-1
histamine phosphate (usp)
H0147 ,
S4117
histamine positive
unii-qwb37t4wzz
qwb37t4wzz ,
FT-0631226
2-(1h-imidazol-4-yl)ethanamine bis(phosphate)
CHEBI:51193 ,
histamine phosphate [mi]
histamine phosphate [mart.]
histamine phosphate [orange book]
histamine phosphate [vandf]
histamine phosphate [ep impurity]
histamine phosphate [who-dd]
histamine phosphate [usp monograph]
SCHEMBL123245
DTXSID7058759
1h-imidazole-4-ethanamine phosphate (1:2)
W-105870
AC-24100
AKOS024462523
histamine diphosphate, 98%
mfcd00064316
bis(phosphoric acid)
CS-5789
HY-A0129
histamine (phosphate)
2-(1h-imidazol-4-yl)ethan-1-amine bis(phosphate)
histamine diphosphate salt
CHEMBL3989520
histamine phosphate,(s)
CCG-267542
2-(1h-imidazol-5-yl)ethanamine;phosphoric acid
D90807
histaminephosphate
BH166413
histamine phosphate (usp monograph)
histamine positiveskin test control
histamine phosphate (mart.)
histamine phosphate (ep impurity)

Roles (1)

RoleDescription
histamine agonistA drug that binds to and activates histamine receptors. Although they have been suggested for a variety of clinical applications, histamine agonists have so far been more widely used in research than therapeutically.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
phosphate salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (85)

TimeframeStudies, This Drug (%)All Drugs %
pre-199053 (62.35)18.7374
1990's20 (23.53)18.2507
2000's5 (5.88)29.6817
2010's6 (7.06)24.3611
2020's1 (1.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (14.29%)5.53%
Reviews1 (1.10%)6.00%
Case Studies4 (4.40%)4.05%
Observational0 (0.00%)0.25%
Other73 (80.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I/II Trial of Peri- and Postoperative Treatment With Histamine Dihydrochloride and Low-dose Interleukin-2 in Patients With Primary Resectable Pancreatic Cancer[NCT05810792]Phase 250 participants (Anticipated)Interventional2024-04-01Not yet recruiting
Open-Label, Multicenter, Effects of Remission Maintenance Therapy With Ceplene® , Given in Conjunction With Low-Dose Interleukin-2, on Immune Response and Minimal Residual Disease in Adult Patients With AML in First Complete Remission[NCT01347996]Phase 484 participants (Actual)Interventional2009-07-31Completed
A Mechanistic Study on Morphine-induced Orthogonal Neural Plasticity for Itch and Pain Processing in Humans (a Relation of Morphine-induced Itch and Pain Processing)[NCT04115462]24 participants (Actual)Interventional2020-01-15Completed
In Vivo Functional Assessment of Histamine Pharmacodynamics in Children[NCT00809692]0 participants (Actual)Interventional2007-09-30Withdrawn(stopped due to Study withdrawn and combined with a new protocol)
Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis[NCT02555852]4,238,504 participants (Actual)Observational2011-09-30Completed
Dermal Blood Flow Response to Escalating Doses of Histamine, Administered by a Skin Prick[NCT04399213]13 participants (Actual)Interventional2019-01-15Completed
Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Immunotherapy With Subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment (Standard of Care) in Patients With Acute Myeloid Leuk[NCT00003991]Phase 3360 participants (Anticipated)Interventional1998-07-31Completed
A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Me[NCT00039234]Phase 30 participants Interventional2002-09-30Active, not recruiting
Détermination de la réactivité cutanée de Volontaires Allergiques au Pollen de Bouleau Contre Des Peptides dérivés de Bet v 1[NCT01719133]Phase 120 participants (Actual)Interventional2008-02-29Completed
Immunologic Profile of Chronically Photodamaged Skin[NCT02889159]Phase 440 participants (Anticipated)Interventional2016-06-06Recruiting
A Randomized Phase II Study to Evaluate the Efficacy of Combined Immunotherapy With Subcutaneous Interleukin-2 and Maxamine in Patients With Metastatic Renal Cell Carcinoma[NCT00005038]Phase 20 participants Interventional1999-06-30Active, not recruiting
A Phase I/II, Open-Label, Multicenter Study of the Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML)[NCT03040401]Phase 1/Phase 215 participants (Anticipated)Interventional2017-02-15Recruiting
Clinical Study to Assess Efficacy, Safety, Tolerability and Optimal Dose Ranging of XC8 in Doses 20, 100 and 200 mg Once Daily in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections (ARVI)[NCT03441373]Phase 2/Phase 3320 participants (Actual)Interventional2016-02-03Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Research Highlights

Safety/Toxicity (1)

ArticleYear
The efficacy and safety of mivacurium in pediatric patients.
BMC anesthesiology, 04-17, Volume: 17, Issue: 1
2017
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (1)

ArticleYear
Neurophysiological and endocrine consequences of immune activity.
Psychoneuroendocrinology, Volume: 14, Issue: 1-2
1989
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (5)

ArticleYear
The efficacy and safety of mivacurium in pediatric patients.
BMC anesthesiology, 04-17, Volume: 17, Issue: 1
2017
Histamine dosage for maximal gastric secretion in Asians - a reappraisal.
Annals of the Academy of Medicine, Singapore, Volume: 10, Issue: 2
1981
The histamine-induced skin reaction in schizophrenic and normal subjects.
The Journal of clinical psychiatry, Volume: 43, Issue: 1
1982
The combined effects of histamine and methacholine on the maximal degree of airway narrowing in normal humans in vivo.
The European respiratory journal, Volume: 1, Issue: 1
1988
Dose-response relationship between objective measures of histamine-induced weals and dose of terfenadine.
Acta dermato-venereologica, Volume: 71, Issue: 3
1991
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]